A recent retrospective cohort study unveiled a crucial connection between obstructive sleep apnea (OSA) and an increased risk ...

Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and headaches. In the long-term, untreated sleep apnea can have serious health ...

Sleep apnea is a sleep disorder marked by interruptions ... Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals ...

More than 60 million Americans battle insomnia, and counting sheep, reading dull books or skipping naps isn't helping. Here ...

A new study published in the BMJ Thorax journal showed that obstructive sleep apnea syndrome (OSAS) may be linked to an ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound ...

Dec. 23, 2024 -- The FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Studies have shown that when ...

An estimated 39 million American adults suffer from obstructive sleep apnea, a condition in which the upper airway is blocked while sleeping.

Share on Pinterest A new study links sleep apnea to changes in key brain regions related to memory. Image credit: Maskot/Getty Images. About 936 million adults around the world have sleep apnea.

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...